Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$3.44 USD
+0.05 (1.47%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Earnings News For AVXL
-
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot
-
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
-
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot
-
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
-
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot
-
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
-
Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
-
Anavex Life Sciences: Fiscal Q2 Earnings Snapshot
-
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
-
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023
-
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot
-
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
-
Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023
-
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot
-
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
-
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot
-
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results
-
Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022
-
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?
-
Can Anavex (AVXL) Run Higher on Strong Earnings Estimate Revisions?